. An early event in atherosclerosis is monocyte adherence to activated endothelial cells 9) . After transmigrating across the endothelial cell layer, monocytes mature into macrophages which phagocytose lipids to become foam cells forming an early fatty streak. Of note, the early stage of atherosclerosis is also characterized by the formation of oxidized low-density lipoprotein (oxLDL) in the vascular wall. According to previous findings, the expression of MIF in macrophages is markedly increased in response to oxLDL 10) . oxLDL further increases the secretion of MIF by macrophages and MIF stimulates oxLDL uptake in an autocrine and paracrine fashion. These data indicate that MIF has in potential role in acceleration of the formation of foam cells.
The evolution of atherosclerosis is characterized by VSMC expansion and activation. These phenotypically modified VSMCs constitute a major part of restenosis 11) and release proinflammatory cytokines, such as tumor necrosis factor alpha (TNF , interleukin-6 (IL-6) and monocyte chemoatractant protein-1
Introduction
Macrophage migration inhibitory factor (MIF) was first described as a product of activated T cells and previous publications led to the recognition that MIF plays a potential role in regulating a broad spectrum of biological events, including inflammation and immune regulation [1] [2] [3] [4] . Importantly, the expression and secretion of MIF is not restricted to immune cells 5) . Vascular endothelial cells (VECs) and smooth muscle cells (VSMCs) were found to produce MIF 6, 7) . Recent publications have suggested that MIF plays a potential role in the progression of atherosclerosis 6) . The pathogenesis of atherosclerosis is characterized by a chronic inflammatory response of the arterial wall to injury 8) . Monocytes and macrophages have (MCP-1) 12, 13) . These cytokines amplify the inflammatory response and serve to sustain the inflammation in advanced plaque. Moreover, the migration of VSMCs from the media to the intima is a key process in the development of both atherosclerosis and restenosis. Interestingly, increased production of MIF has been observed in VSMCs during the progression of atherosclerotic plaque evolution in humans and in a hypercholesterolemic rabbit model 6, 14) . Recent in vivo studies have provided evidence of the role of MIF in accelerated atherosclerosis and re-stenosis 15) . Pan et al. demonstrated that MIF / /LDL-R / double knockout mice had reduced intimal thickening in the aortic arch and the atherosclerotic lesion area in the abdominal aorta, accompanied by diminished VSMC proliferation and proteolytic capacity 16) . These observations suggested that MIF contributes to advanced complicated lesion formation in atherosclerosis; however, the functional role of MIF in the migration of VSMCs has not been elucidated.
In the present study, we obtained direct in vitro evidence that MIF acts as a mediator of the migration of VSMCs by studying the effects of MIF on the ox-LDL-mediated migration of VSMCs.
Methods

Materials
Rabbit anti-MIF polyclonal antibody, and recombinant human MIF and A10 cell lines, derived from rat embryonic aortic smooth muscle cells, were generous gifts from Dr. Nishihira (Hokkaido University). Anti-actin antibody was obtained from Sigma (St. Louis, MO).
Cell Culture
Rat A10 cells were cultured in DMEM supplemented with 10% heat-inactivated FCS at 37 under 5% CO2, and subcultured every 3 days. DMEM supplemented with 1%FCS was used in the secretion and expression assay of MIF. Serum-free DMEM was used in the migration assay to reduce the effect of serum. Cell viability in serum-free medium and 1%FCS-containing medium was analyzed by trypan blue exclusion. No significant loss of viable A10 cells was observed under these conditions.
Preparation of Oxidized LDL
LDL (d 1.019-1.063) was isolated from fresh normal human plasma by ultracentrifugation. LDL was oxidized by incubating LDL (200 g of protein/ mL) with 5 M CuSO4 in phosphate-buffered saline without EDTA for 20 h at 37 10, 17) . The degree of oxidation was assessed by the increase of electro-negative mobility in an agarose gel. In addition, the levels of oxidized lipids were evaluated by measuring thiobarbituric acid-reactive substance (TBARS) levels.
ELISA Analysis of MIF
For the quantification of MIF, we performed a one-step sandwich ELISA consisting of a solid phase anti-MIF antibody and horseradish peroxidase-conjugated anti-MIF antibody using IDLISA Rat/Mouse MIF (Sapporo Immuno Diagnostic Laboratories, Sapporo, Japan).
Immunoblot Analysis
Cells were lysed in radioimmunoprecipitation assay buffer (150 mM NaCl, 1% NP-40, 0.5% DOC, 0.1% SDS, 50 mM Tris pH7.5) containing protease inhibitors (Complete, Mini, EDTA-free, Roche Diagnostics Co, Indianapolis, IN), and disrupted by aspiration through a 21-gauge needle. After incubation on ice for 30 min and micro-centrifugation for 10 min, the supernatants were collected and protein concentration was determined by DC Protein Assay (Bio-Rad, Hercules, CA), according to the manufacturer's recommendations. Equal amounts of cellular proteins were fractionated on SDS gels, transferred to polyvinylidine difluoride membranes (Millipore, Bedford, MA), and analyzed by Western blotting. The expression of MIF was revealed with an anti-MIF polyclonal antibody in combination with peroxidase-labeled secondary antibody and blots were developed by Super Signal West Femto Maximum Sensitivity Substrate (Pierrce, Rockford, IL). Blots were reprobed with anti-actin antibody.
Migration Assay
Migration of A10 cells was measured by the migration of cells through a Matrigel-coated Chemotaxicell chamber (KURABO, Osaka, Japan). After treatment with MIF siRNA or control siRNA, cells were cultured in DMEM containing 1%FCS with or without oxLDL for 12 h. Cells were plated in the upper chamber and allowed to migrate for 12 h. Noninvasive cells were removed from the upper chamber with a cotton swab, and migrating cells adhering to the underside of the filter were fixed, and stained with Diff Quick solution. Ten random fields per filter were counted. All experiments were performed independently and in triplicate.
Transfection with siRNA
The RNAi technique is used to down-regulate the expression of specific genes in living cells by introducing a homologous double-stranded RNA, and 21-base siRNAs are potent mediators of the RNAi effect in mammalian cells. The nucleotide sequences of dsRNA and complimentary dsRNA for mouse mRNA were 5'-CCGCAACUACAGUAAGCUGdTdT-3' and 5'-CAGCUUACUGUAGUUGCGGdTdT-3', respectively. As a control RNA duplex, 5'-GCGCGCUUUGUAGGAUUCGdTdT-3' and 5'-CGAAUCCUACAAAGCGCGCdTdT-3' were used. A10 cells in culture dishes (60 mm in diameter) containing DMEM supplemented with 1%FCS were transfected with either MIF siRNA or control RNA duplex using siFECTOR (B-Bridge, Sunnyvale, CA) according to the manufacturer's protocol.
Statistical Analysis
Significance of difference was determined by oneway analysis of variance (ANOVA) following Tukey's test for the comparison of individual treatment groups. P 0.05 was considered statistically significant.
Results
Effect of oxLDL on MIF Secretion by A10 Cells
oxLDL has been reported to induce macrophage and endothelial MIF expression 10, 14) ; therefore, we evaluated the effect of oxLDL on MIF production and release by VSMCs. The preparation of oxLDL was described in the Methods. TBARS levels were increased in oxLDL compared to native LDL (44.0 versus 3.2 nmol MDA/mg LDL protein), and the increased oxidation of LDL was also confirmed by the increase of electro-negative mobility in an agarose gel (Fig. 1A) . A10 cells were cultured in DMEM containing 1%FCS for 24 h and cells were stimulated with 50 g/mL of oxLDL. The concentration of MIF in the supernatant was measured by ELISA, as described in Methods. As compared with control and native LDL, a marked increase of MIF content was observed in the supernatant of oxLDL-treated A10 cells (Fig. 1B) , and the effect of oxLDL on MIF release was observed in a dosedependent manner (Fig. 1C) .
Effect of oxLDL on MIF Protein in A10 Cells
The effect of oxLDL on the expression of MIF protein in A10 cells was examined by immunoblotting using anti-MIF antibody. As shown in Fig. 2 , the expression of MIF protein was markedly increased by stimulation of oxLDL at 6, 12 and 24 h compared to the stimulation of native LDL.
Effect of Recombinant MIF on the Migration of A10 Cells
To evaluate the functional role of MIF induced by oxLDL in A10 cells, we examined the migration of A10 cells in the presence of recombinant MIF using an established protocol. The increase in the migration of A10 cells was significantly associated with the concentration of MIF (p 0.001, ANOVA). MIF enhanced the migration of A10 cells in a dose-dependent manner (Fig. 3) .
Effect of Inhibition of MIF Expression in A10 Cells
Since the potential role of oxLDL in the migration of vascular endothelial cells (VECs) has been shown in previous reports, it seemed reasonable to hypothesize that oxLDL-induced release of MIF is asso- (Fig. 4B) . Thus, we confirmed the inhibition of oxLDL-dependent induction of MIF in A10 cells by MIF siRNA. Finally, we studied the effect of MIF siRNA on the oxLDLinduced migration of A10 cells. The cells were treated with MIF siRNA or control siRNA for 48 h, following stimulation with oxLDL (50 g/mL) for 12 h. As shown in Fig. 5 , MIF siRNA treatment led to the reduction of oxLDL-mediated migration of A10 cells, whereas control siRNA did not affect the upregulation of A10 cell migration induced by the stimulation of oxLDL.
Discussion
oxLDL has been reported to induce macrophage and endothelial MIF expression 10, 14) . In the present study, we demonstrated that the expression and secretion of MIF by A10 cells was increased by the stimulation of oxLDL. Therefore, oxLDL seems to be a potent stimulator for the induction of MIF during the progression of atherosclerosis. We also observed that recombinant MIF enhanced the migration of A10 cells. The range of MIF concentration in this study was 1-500 ng/mL, and a significant effect of MIF on the migration of A10 cells was observed at concentrations of MIF that are within the range for those reported under pathological conditions 18, 19) . We also observed that knockdown of the expression of MIF by siRNA abolished the oxLDL-mediated migration of A10 cells. The transient expression of MIF by VSMCs observed in atherogenic lesions of a hypercholesterolemic rabbit model 6) may support our present findings. In addition, the up-regulation of MIF production by VSMCs over different stages of human atherosclerosis was also reported previously 14) . These observations suggest the involvement of MIF in VSMC migration during advanced plaque formation. Of note, MIF secretion is stimulated by cytokines such as TNF and IL-1 5, 20) , and upregulation of MIF was observed in VECs and VSMCs following inflammatory stimulation 7, 21) . These observations suggest that inflammatory response is also important for the production of MIF in atherogenesis. Furthermore, the present data support the previous findings that MIF enhances oxLDL uptake by macrophages in an autocrine and paracrine fashion. Macrophage-derived MIF may also stimulate the migration of VSMCs concomitant with the effect of VSMC-derived MIF induced by oxLDL. Thus, MIF acts as an enhancer of the progression of atherosclerosis, involving the initiating role of atherogenesis, such as fatty streak formation, and the advanced stage of atherosclerosis.
The enhanced expression of endothelial adhesion molecules, such as VCAM-1, ICAM-1, 1 and 2-integrin and P-and E-selectin, have been suggested as a key process during the progression of atherogenesis. A recent publication showed that treatment with anti-MIF antibody led to the reduction of a variety of inflammatory mediators typically associated with atherosclerosis, including circulating levels of fibrinogen and IL-6 together with the reduction of local aortic expression of ICAM-1 in apolipoprotein E-deficient mice 22) . Lin et al. previously showed that MIF stimulates ICAM-1 expression in endothelial cells 6) . These observations support our previous findings and present data, indicating that MIF has a potential role in atherogenesis.
Although intracellular formation of MIF/JAB1 complexes 23) , and CD74-mediated triggering of the mitogen-activated protein kinase (MAPK) pathway by MIF [24] [25] [26] [27] have been implicated, the molecular basis of the function of MIF is still incompletely understood, and the contribution of the MIF-mediated signaling pathway has not been clarified. MIF has been shown to regulate the migration of endothelial cells via activation of MAPK and phosphatidyl inositol 3 kinase (PI3K) 28) ; therefore, we speculate that the effect of MIF on the migration of VSMCs may be associated with these molecules. Furthermore, the potential role of MIF in association with tumor invasion and metastasis via the Rho-dependent pathway has been reported previously 29) . In the process of tumor invasion and metastasis, migration activity is accompanied by stress fiber formation and focal adhesion assembly through a Rho/Rho-associated kinase pathway 29) . These observations indicate that the effect of MIF on the migration Recently, increased plasma concentration of MIF in obese subjects has been reported 30) . These increases in MIF are related to increases in body mass index and serum levels of free fatty acids and C-reactive protein.
In addition, metformin suppresses plasma MIF concentrations in the obese and this action of metformin may contribute to the antiatherogenic effect. Herder et al. demonstrated the association of systemic concentrations of MIF with impaired glucose tolerance and type 2 diabetes 31) . These clinical findings suggest the contribution of MIF to the development of atherosclerosis and support our hypothesis. The MIF inhibitor has been shown to inhibit the pro-inflammatory activity of MIF 32) , and neutralizing anti-MIF antibody has been shown to inhibit the progression of atherosclerosis in vivo 15, 21) ; however, these therapies have not been established in humans and further study is needed to confirm the effect of MIF blockade on the prevention of cardiovascular events.
In conclusion, MIF is involved in the initiation of the migration of VSMCs and may be associated with the development of advanced lesions during the course of atherogenesis.
